Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bacterial Phylum Chlamydiae01:29

Bacterial Phylum Chlamydiae

The phylum Chlamydiae or Chlamydiota is composed of a single order, Chlamydiales. This phylum consists entirely of obligate intracellular parasites that infect eukaryotic hosts. While human pathogens within this group have been studied extensively, the phylum encompasses many species capable of interacting with various eukaryotic organisms. Members of Chlamydiae are typically small cocci, approximately 0.5 μm in diameter, and exhibit a distinctive developmental cycle. As is characteristic of...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Activity of chemotherapy in mesenchymal chondrosarcoma: a multicentre retrospective analysis within the Italian Sarcoma Group network.

ESMO open·2026
Same author

Trabectedin-olaparib combination or trabectedin in advanced soft tissue sarcomas after failure of anthracycline-based treatment (TOMAS2): a randomized phase II study from the Italian Sarcoma Group.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

TB outpatient care in a high-income, low-incidence country.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2024
Same author

TRAbectedin in adVanced rEtroperitoneal well differentiated/dedifferentiated Liposarcoma and Leiomyosarcoma (TRAVELL): results of a phase II study from the Italian Sarcoma Group.

ESMO open·2024
Same author

Effects of insulin therapy optimization with sensor augmented pumps on glycemic control and body composition in people with cystic fibrosis-related diabetes.

Frontiers in endocrinology·2023
Same author

Humoral and cell-mediated immune responses to BNT162b2 vaccine against SARS-CoV-2 in people with cystic fibrosis.

Vaccine·2023
Same journal

How stable are antimicrobial susceptibility profiles in serial clinical isolates? A retrospective study informing repeat-testing strategies.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same journal

Impact of low-dose chest CT and multiplex PCR on antibiotic usage for community-acquired pneumonia: multicentre prospective controlled before-after study with cluster randomisation (CAP-NEXT study).

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same journal

Clinical Microbiology and Infection: how did we do in 2025?

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same journal

Automate the work, not the decision: aligning expectations for AI in clinical microbiology.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same journal

Doxycycline prophylaxis and gonococcal resistance: reassurance, residual signals, and the case for surveillance.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same journal

Oral metronidazole versus clindamycin to treat bacterial vaginosis in pregnancies at risk for preterm labor.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
See all related articles

Related Experiment Video

Updated: Jun 25, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Chlamydophila pneumoniae.

F Blasi1, P Tarsia, S Aliberti

  • 1Institute of Respiratory Diseases, University of Milan, IRCCS Fondazione Ospedale Maggiore, Milan, Italy. francesco.blasi@unimi.it

Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
|February 18, 2009
PubMed
Summary
This summary is machine-generated.

Chlamydophila pneumoniae is a common cause of respiratory infections and may be linked to atherosclerosis and neurological issues. Treatment typically involves tetracyclines or erythromycin, with newer antibiotics showing promise.

More Related Videos

Forward Genetic Approaches in Chlamydia trachomatis
09:03

Forward Genetic Approaches in Chlamydia trachomatis

Published on: October 23, 2013

Related Experiment Videos

Last Updated: Jun 25, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Forward Genetic Approaches in Chlamydia trachomatis
09:03

Forward Genetic Approaches in Chlamydia trachomatis

Published on: October 23, 2013

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Public Health

Background:

  • Chlamydophila pneumoniae is a widespread bacterium responsible for a significant portion of community-acquired pneumonia, pharyngitis, bronchitis, and sinusitis.
  • This pathogen affects both immunocompetent and immunocompromised individuals and is implicated in exacerbations of chronic respiratory conditions like asthma and bronchitis.
  • Emerging evidence suggests a potential role for Chlamydophila pneumoniae in the pathogenesis of atherosclerosis and central nervous system disorders.

Purpose of the Study:

  • To review recent findings on the involvement of Chlamydophila pneumoniae in human diseases.
  • To highlight the diagnostic methods and therapeutic strategies for Chlamydophila pneumoniae infections.

Main Methods:

  • Literature review of recent scientific data.
  • Analysis of studies investigating the role of Chlamydophila pneumoniae in various human pathologies.
  • Evaluation of current and emerging diagnostic and treatment modalities.

Main Results:

  • Chlamydophila pneumoniae is a frequent cause of respiratory infections and is associated with chronic respiratory disease exacerbations.
  • The bacterium is increasingly recognized for its potential contribution to atherosclerosis and neurological conditions.
  • Microimmunofluorescence is the current gold standard for serological diagnosis, with molecular methods poised to become future references.

Conclusions:

  • Chlamydophila pneumoniae plays a significant role in human infectious diseases, extending beyond typical respiratory infections.
  • Effective treatment options include established antibiotics like tetracyclines and erythromycin, alongside newer antimicrobial agents.
  • Further research is warranted to fully elucidate the bacterium's role in chronic diseases and to optimize diagnostic and therapeutic approaches.